ALX Oncology Holdings Inc.
Price Action
Technical Summary
EMERGING TRENDALX Oncology Holdings Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 76), indicating performance broadly in line with the market. Earnings growth of 43% provides fundamental context to the price action. However, price is extended 21% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.74 | +25.93% | ABOVE |
| 50 SMA | $1.81 | +20.71% | ABOVE |
| 100 SMA | $1.94 | +12.65% | ABOVE |
| 150 SMA | $1.78 | +23.21% | ABOVE |
| 200 SMA | $1.73 | +26.93% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ALXO in an uptrend right now?
ALXO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ALXO overbought or oversold?
ALXO's RSI (14) is 63. The stock is in neutral territory, neither overbought nor oversold.
Is ALXO outperforming the market?
ALXO has a Relative Strength (RS) Rating of 76 out of 99. ALXO is performing about average compared to the market.
Where is ALXO in its 52-week range?
ALXO is trading at $2.19, which is 82% of its 52-week high ($2.66) and 79% above its 52-week low ($0.44).
How volatile is ALXO?
ALXO has a Beta of 1.37 and 52-week volatility of 117%. It's more volatile than the S&P 500 - expect bigger swings.